| Literature DB >> 25833964 |
Jeremy A Goettel1, Subhabrata Biswas2, Willem S Lexmond1, Ada Yeste3, Laura Passerini4, Bonny Patel3, Siyoung Yang5, Jiusong Sun2, Jodie Ouahed1, Dror S Shouval1, Katelyn J McCann6, Bruce H Horwitz7, Diane Mathis5, Edgar L Milford8, Luigi D Notarangelo9, Maria-Grazia Roncarolo10, Edda Fiebiger1, Wayne A Marasco2, Rosa Bacchetta4, Francisco J Quintana3, Sung-Yun Pai11, Christoph Klein12, Aleixo M Muise13, Scott B Snapper14.
Abstract
Mice reconstituted with a human immune system provide a tractable in vivo model to assess human immune cell function. To date, reconstitution of murine strains with human hematopoietic stem cells (HSCs) from patients with monogenic immune disorders have not been reported. One obstacle precluding the development of immune-disease specific "humanized" mice is that optimal adaptive immune responses in current strains have required implantation of autologous human thymic tissue. To address this issue, we developed a mouse strain that lacks murine major histocompatibility complex class II (MHC II) and instead expresses human leukocyte antigen DR1 (HLA-DR1). These mice displayed improved adaptive immune responses when reconstituted with human HSCs including enhanced T-cell reconstitution, delayed-type hypersensitivity responses, and class-switch recombination. Following immune reconstitution of this novel strain with HSCs from a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, associated with aberrant FOXP3 function, mice developed a lethal inflammatory disorder with multiorgan involvement and autoantibody production mimicking the pathology seen in affected humans. This humanized mouse model permits in vivo evaluation of immune responses associated with genetically altered HSCs, including primary immunodeficiencies, and should facilitate the study of human immune pathobiology and the development of targeted therapeutics.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25833964 PMCID: PMC4473116 DOI: 10.1182/blood-2014-12-618363
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113